Relationship Between Immune Gene Signatures and Clinical Response to PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Advanced Solid Tumors

Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/2051-1426-3-s2-p80
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Immunogenicity of Pembrolizumab in Patients With Advanced Tumors

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2019English

Assessment of Subcutaneous vs Intravenous Administration of Anti–PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors

JAMA Oncology
Cancer ResearchOncology
2019English

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Breast Care
SurgeryOncology
2016English

O3-2-5a Phase I Trial of BI 754091, a Programmed Death Receptor 1 (PD-1) Inhibitor, in Patients With Advanced Solid Tumors

Annals of Oncology
MedicineOncologyHematology
2018English

A Phase 1 Study of Oral Ridaforolimus in Pediatric Patients With Advanced Solid Tumors

Oncotarget
Oncology
2016English

PD-1 Expression and Clinical PD-1 Blockade in B-Cell Lymphomas

Blood
BiochemistryImmunologyCell BiologyHematology
2018English

P2.01-21 Antigen Cascade Triggering Correlates With Prolonged Survival in Advanced NSCLC Patients Undergone PD-1 Blockade With Nivolumab.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.13-32 Comparison Between Immune-Mediated Pneumonitis and Pneumonia in Patients Treated With PD-1/PD-L1 Therapy

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Phase I Study of Nivolumab, an Anti-Pd-1 Antibody, in Patients With Malignant Solid Tumors

Investigational New Drugs
OncologyPharmacology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy